Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Pemphigus Foliaceus
Symptoms, Doctors, Treatments, Advances & More
Overview
Find a Doctor
Latest Advances
Clinical Trials
Condition 101
About Pemphigus Foliaceus
What are the alternative names for Pemphigus Foliaceus?
PF
Top Global Doctors
For Pemphigus Foliaceus
Bookmark
Click to see options
VW
Elite
Victoria P. Werth
Dermatology
Philadelphia, PA
Bookmark
Click to see options
SG
Elite
Sergei A. Grando
Dermatology
Orange, CA
Bookmark
Click to see options
AP
Elite
Aimee S. Payne
Dermatology
Philadelphia, PA
Bookmark
Click to see options
ES
Elite
Enno W. Schmidt
Luebeck, SH, DE
Bookmark
Click to see options
MD
Elite
Maryam Daneshpazhooh
Tehran, IR
Bookmark
Click to see options
KB
Elite
Kamran Balighi
Tehran, IR
Latest Advances
On Pemphigus Foliaceus
Condition:
Hard-to-Heal Ulcers in Patients with Pemphigus Vulgaris
Journal:
Journal of wound care
Treatment Used:
Topical Nanocolloidal Silver Formulation vs. Eosin 2% solution
Number of Patients:
32
Published —
November 11, 2020
This study examined the effect of a nanocolloidal silver-based gel called SilvoGel versus eosin solution in patients with immunobullous (skin) disease.
Condition:
Chronic Lymphocytic Leukemia-associated Paraneoplastic Pemphigus
Journal:
Scientific reports
Treatment Used:
Ibrutinib
Number of Patients:
842
Published —
October 02, 2020
The study researched chronic lymphocytic leukemia-associated paraneoplastic pemphigus.
Clinical Trials
For Pemphigus Foliaceus
Clinical Trial
Status:
Not yet recruiting
Participants:
20
Start Date:
May 1, 2021
Prospective Analysis of the Th17 Cellular Response in Pemphigus Vulgaris Patients Treated With Corticosteroids and Optional Adjuvants
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 3
Intervention Type:
Drug
Participants:
594
Start Date:
March 29, 2021
Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis